- Home
- SNES vs PHIO Comparison
SNES vs PHIO Comparison
Compare SNES & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | PHIO |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 12.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNES | PHIO |
|---|---|---|
| Price | $2.57 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $10.67 |
| AVG Volume (30 Days) | 50.4K | ★ 406.3K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | $41.52 | N/A |
| Revenue Next Year | $77.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.37 | N/A |
| 52 Week Low | $1.30 | $0.97 |
| 52 Week High | $6.24 | $9.79 |
Technical Indicators
Market Signals| Indicator | SNES | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 32.05 |
| Support Level | $2.70 | $1.07 |
| Resistance Level | $2.94 | $1.20 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 9.80 | 14.03 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.